Study published in Front Immunol. on co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis in STAM™

We are pleased to introduce a study on non-alcoholic steatohepatitis (NASH) may promote the development and exacerbation of psoriasis in STAM™ mice.

This study was published by Kawasaki Medical School in Frontiers in Immunology.


Title: Co-occurrence of non-alcoholic steatohepatitis exacerbates psoriasis associated with decreased adiponectin expression in a murine model

(Takezaki D et al., Front. Immunol., 2023)   Article Link ► [Read Article]


In STAM™ mice with advanced NASH pathology treated with imiquimod (IMQ) to induce psoriasis pathology (STAM™+IMQ group),

  • Epidermal thickening and blood IL-17 and TNF-α levels were significantly increased compared to normal, STAM™, and IMQ group
  • Blood adiponectin levels were significantly decreased compared to normal and IMQ group


This study suggests that NASH exacerbates psoriasis and that adiponectin may be a potential therapeutic target in cases of combined NASH and psoriasis. For more information, please see this paper.


It has been known that psoriasis is a complication of NAFLD and more severe in patients with NAFLD than in those with normal psoriasis. Psoriasis patients have also been shown to have a higher incidence of NAFLD compared to healthy individuals. However, the underlying causal relationship between the two diseases has not been clarified.

The results of this study demonstrate one aspect of the causal relationship between NAFLD and psoriasis, and the usefulness of STAM™ mice for basic studies and drug efficacy evaluation studies for NASH/NAFLD.


If you have a NASH/NAFLD-related study project, we recommend that you consider in vivo studies using STAM™ mice.

If you have any interest or questions, please feel free to contact us.


■About STAM™ mice [Click here]

■About IMQ-induced psoriasis mice [Click here]